Genentech, Inc.

Mark Ultsch

Michelle Schaffer

Felix Vajdos

Wei Ey Li

Robert A Lazarus

Daniel Kirchhofer

Daniel J Burdick

Yingnan Zhang

Maureen H Beresini

Nicholas Skelton

Charles Eigenbrot, Jr

John Quinn

James A Wells

Brian C Cunningham

Michael George Mulkerrin

Abraham M DeVos

The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

Compositions and methods for treating cardiovascular disease

Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.

Crystallization of IGF-1

Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-l to which a candidate indirect agonist binds for structure-based drug design.

Selecting ligand agonists and antagonists

Growing community of inventors

Mill Valley, CA, United States of America

Mark Ultsch